$VTEX

Gomes Andre Spolidoro Ferreira sold $11K of VTEX

Gomes Andre Spolidoro Ferreira (Chief Strategy Officer) sold 3,000 shares of VTEX (VTEX) at $3.57 on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gomes Andre Spolidoro Ferreira
Published Aug 18, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTEX
Neutral
low confidence
Mentioned
$VTEX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTEXNeutralLow
01

Why it matters

This is a routine insider sale under a pre-arranged 10b5-1 plan, typically viewed as lower-signal than discretionary selling.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental information to drive repricing.

03

What to watch

The filing does not disclose any new company performance, guidance, or risk event; the only actionable element is the timing and size of the sale.

Relevance 2/10Novelty 2/10Timing: Filed 2026-08-18, transaction dated 2026-08-17.

Background

The article is an SEC Form 4 insider transaction disclosure for VTEX, reported by its Chief Strategy Officer.

Company-level read

Ticker impact

$VTEXNeutralLow confidence
Context

SEC Form 4 shows VTEX CSO Gomes Andre Spolidoro Ferreira sold 3,000 shares at $3.57 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or financial disclosure.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because it is a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations, so traders may ignore it.

Key entities

  • VTEX

    Company whose insider transaction was disclosed on SEC Form 4.

  • Gomes Andre Spolidoro Ferreira

    Chief Strategy Officer who sold 3,000 shares.

  • 10b5-1 plan

    Pre-arranged plan that reduces interpretive weight of the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTEXMed

VTEX (VTEX) Just Turned A Profit Corner, But Growth Is Slowing

VTEX (NYSE:VTEX) reported Q2 2026 results showing improved profitability with non-GAAP income from operations up 62.4% YoY to $13.8M, and free cash flow up 79.1% to $12.7M. However, revenue growth slowed to 1.3% YoY on an FX-neutral basis, with management expecting flat growth for Q3. The company repurchased 6.2M shares for $23.2M during the quarter.

$VTEXMedAI 8/10

VTEX (VTEX) Q2 2026 Earnings Call Transcript

VTEX reported Q2 2026 results in an earnings call. GMV was $5.7B, up 7% FX-neutral. Subscription revenue was $63.8M, up 1.3% FX-neutral. Non-GAAP operating income rose 62% to $13.8M, with a 21.4% margin. Free cash flow was $12.7M, up 79%. Q3 guidance calls for flat FX-neutral subscription growth.

$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

$VTEXMed

VTEX (VTEX): Financial results for Q2 2026

VTEX (VTEX) furnished an SEC Form 6-K — earnings release. VTEX Reports Second Quarter 2026 Financial Results Subscription revenue grew 11.4% (+1.3% FXN), with GMV up 17.8% (+7.0% FXN) Non-GAAP income from operations increased 62.4% to US$13.8 million, reaching a 21.4% margin Free cash flow increased 79.1% to US$12.7 million, reaching a